"10.1371_journal.pone.0151800","plos one","2016-03-24T00:00:00Z","Mary Beth Callan; Mark E Haskins; Ping Wang; Shangzhen Zhou; Katherine A High; Valder R Arruda","Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Center for Cellular and Molecular Therapeutics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: MBC MEH KAH VRA. Performed the experiments: MBC VRA PW. Analyzed the data: MBC VRA MEH PW. Contributed reagents/materials/analysis tools: SZ. Wrote the paper: VRA MBC MEH KAH.","K.A.H. holds patents related to AAV-FIX, in which she has waived any financial interest. K.A.H. is now the President and Chief Scientific Officer of Spark Therapeutics, however at the time that this work was planned and executed she was the Director of the Center for Cell and Molecular Therapeutic at The Children’s Hospital of Philadelphia. M.E.H. is a stockholder of BioMarin Inc. There are no further patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2016","03","Mary Beth Callan","MBC",6,TRUE,4,3,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
